Study Name:
A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy (SKYSCRAPER-15; GO45006)
Targeted Disease(s):
Lung Cancer
Purpose of Study:
The purpose of this study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab administered to participants with PD-L1 positive Stage IIB, IIIA and select IIIB (T3N2) non-small cell lung cancer (NSCLC) following resection and adjuvant chemotherapy
Study Dates:
December 1, 2023 - June 30, 2029
Type of Study:
Pre-Market
Study Design:
Controlled Design
Study Location:
Nationwide
Funding Source:
Hoffmann-La Roche
ClinicalTrails.gov Identifier:
NCT06267001
https://clinicaltrials.gov/study/NCT06267001
